Financial Performance - Yisheng Pharmaceutical (002566) reported a net profit decline of 43.71% year-on-year for the first half of 2025, with total revenue of 328 million yuan, down 5.75% from the previous year [1] - The gross profit margin decreased to 75.15%, a drop of 2.02% year-on-year, while the net profit margin fell to 6.05%, down 36.94% [1] - The company’s total expenses (selling, administrative, and financial) reached 219 million yuan, accounting for 66.83% of revenue, an increase of 2.16% year-on-year [1] Cash Flow and Financial Ratios - The company experienced a significant increase in financial expenses by 502.37% due to reduced interest income [3] - The net cash flow from investment activities increased by 100.86%, attributed to higher cash recovered from investments compared to the previous year [3] - The company’s return on invested capital (ROIC) was reported at 2.08%, indicating historically weak capital returns [3] Accounts Receivable and Inventory - The accounts receivable to profit ratio reached 312.96%, suggesting potential issues with cash collection [4] - The inventory to revenue ratio stood at 241.32%, indicating a high level of inventory relative to sales [4] Strategic Focus - The company plans to increase its research and development efforts to meet market demands, addressing concerns about the lack of new product development in traditional Chinese medicine [5]

Core Points - The company has not distributed cash dividends or bonus shares during the reporting period [3] - The company has implemented a rectification plan to address issues related to shareholding by proxy, ensuring accurate disclosure of shareholder information [5] - The board of directors and supervisory board have both approved the 2025 semi-annual report, confirming its compliance with legal and regulatory requirements [10][12] Company Overview - The company is identified as Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. with the stock code 002566 [1] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [6][7] Financial Information - The company has not reported any preferred shareholders or related data during the reporting period [8] - The company has not issued any bonds that are still in existence as of the date of the semi-annual report [9]

Core Viewpoint - Yisheng Pharmaceutical announced the approval of its 2025 semi-annual report and summary by the company's ninth board of directors during its second meeting [2] Group 1 - The announcement was made on the evening of August 22 [2] - The report includes financial performance and operational highlights for the first half of 2025 [2]

Core Viewpoint - Yisheng Pharmaceutical announced the approval of its 2025 semi-annual report and summary by the second meeting of the ninth supervisory board [2] Group 1 - The announcement was made on the evening of August 22 [2] - The report includes financial performance and operational updates for the first half of 2025 [2]

Core Insights - Yisheng Pharmaceutical (002566) reported that as of August 20, 2025, the total number of shareholders is 21,920 [1] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder statistics [1]

Core Viewpoint - Yisheng Pharmaceutical reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 328 million yuan, a year-on-year decrease of 5.75% [1] - The net profit attributable to shareholders was 18.76 million yuan, down 43.71% compared to the previous year [1] - Basic earnings per share were 0.0567 yuan, reflecting a decline of 43.69% year-on-year [1] Dividend Policy - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves [1]

Core Viewpoint - The board of directors of Jilin Province Jianshan Yisheng Pharmaceutical Co., Ltd. convened its second meeting of the ninth session on August 22, 2025, to review and approve the 2025 semi-annual report and its summary [1][2]. Group 1 - The meeting was attended by all 9 directors, and the resolutions were passed with unanimous consent (9 votes in favor, 0 against, 0 abstentions) [1]. - The meeting was legally valid and complied with the provisions of the Company Law and the Articles of Association [1]. - The full text of the 2025 semi-annual report is available on the designated information disclosure website, Juchao Information Network [1].

Core Points - The company held its ninth supervisory board's second meeting on August 22, 2025, where all three attending supervisors approved the 2025 semi-annual report [1][2] - The supervisory board confirmed that the procedures for preparing and reviewing the semi-annual report complied with relevant laws and regulations, ensuring the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] Summary by Sections - **Meeting Details** - The meeting was convened and conducted in accordance with the Company Law and relevant regulations, with all three supervisors present [1] - **Approval of Semi-Annual Report** - The supervisory board unanimously approved the 2025 semi-annual report with a vote of 3 in favor, 0 against, and 0 abstentions [1] - **Report Verification** - The supervisory board verified that the report's preparation and review processes met legal and regulatory standards, confirming its authenticity and completeness [1]

益盛药业8月22日晚间发布公告称，公司第九届第二次董事会会议于2025年8月22日在公司四楼会议室召 开。会议审议了《2025年半年度报告及其摘要》等文件。 （文章来源：每日经济新闻） ...

（文章来源：每日经济新闻） 益盛药业8月22日晚间发布半年度业绩报告称，2025年上半年营业收入约3.28亿元，同比减少5.75%；归 属于上市公司股东的净利润约1876万元，同比减少43.71%；基本每股收益0.0567元，同比减少43.69%。 ...